Form 4: Theravance Biopharma Executive Aine Miller Sells Shares to Cover Tax Obligations

Theravance Biopharma's SVP, Aine Miller, sold 10,076 ordinary shares to cover tax obligations related to vesting restricted stock units.

Summary

• Aine Miller, SVP at Theravance Biopharma, sold 10,076 ordinary shares on November 20, 2024.
• The shares were sold at a price of $9.97 per share.
• This transaction was to cover tax obligations arising from the vesting of previously granted restricted stock units.
• The sale was not an open market transaction but a share withholding transaction with the issuer.
• Following the transaction, Aine Miller beneficially owns 150,556 ordinary shares.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Share sales by executives to cover tax obligations are a common practice across the pharmaceutical and biotech industries.
• Many companies use restricted stock units as part of their compensation packages, leading to similar tax-related sales.
• This transaction is consistent with standard practices for executives managing their equity compensation.

Stakeholder Impact

• The share sale has a minimal impact on shareholders as it is a routine transaction for tax purposes.
• The transaction does not affect the company's operations or financial health.

Key Dates

Keywords

Theravance Biopharma, insider trading, share sale, stock transaction, restricted stock units, tax obligations, Form 4, Aine Miller